Aprea Therapeutics APRE 深 沪
等待开盘 01-30 09:30:00 美东时间
0.59
-0.174
-22.78%
华盛通- 最 高0.76
- 今 开0.76
- 成交量 556.58万股
- 最 低 0.548
- 昨 收 0.7641
- 总市值 372.33万
- 52周最高 3.88
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 0.548
- 委 比 64.86%
- 总股本 631.07万
- 历史最高 1062.20
- 量 比 89.18
- 振 幅 27.75%
- 历史最低 0.548
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
今天 10:54
Aprea Therapeutics prices $5.6M private placement
Aprea Therapeutics (NASDAQ: APRE) said on Thursday that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors, as well as certain insider...
01-29 21:52
Aprea Therapeutics Commences ~$5.6M Offering Of 6.289M Common Shares, Warrants At $0.89 Apiece
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage
01-29 21:26
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Aprea Therapeutics Inc. has received a deficiency letter from the Nasdaq Listing Qualifications Department, notifying the company that its common stock has traded below the minimum required bid price of $1.00 per share for 30 cons
01-26 15:49
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
Aprea Therapeutics ( ($APRE) ) has issued an update. On January 9, 2026, Aprea ...
01-10 06:09
Aprea Therapeutics Updates 2025 Progress, Cash Runway To Support Operations Through Q1 2027
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy
2025-12-18 21:39
Aprea Therapeutics Enters $3.1M Securities Purchase Agreement Through Sale Of 2,623,023 Shares And Warrants At A Combined Price Of $1.165
Financing from new and existing healthcare focused investorsThe proceeds are expected to extend the Company's cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that
2025-12-09 21:38
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.34) by 38.24 percent. This is a 26.56 percent increase over losses of $(0.64) per share
2025-11-12 21:40
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinica...
2025-10-28 01:27
Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
2025-10-24 20:35
